小6s
Lv1
75 积分
2021-03-03 加入
-
中国中重度银屑病疾病负担和未满足治疗需求的系统综述
3天前
已完结
-
β blockers switched to first-line therapy in hypertension
9天前
已完结
-
One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study
11天前
已完结
-
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
15天前
已完结
-
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
20天前
已完结
-
Facts and hopes on cancer immunotherapy for small cell lung cancer
22天前
已完结
-
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial
23天前
已完结
-
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study
23天前
已完结
-
The landscape of T cell antigens for cancer immunotherapy
29天前
已完结
-
Protein degraders enter the clinic - a new approach to cancer therapy
1个月前
已完结